Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P32241
UPID:
VIPR1_HUMAN
Alternative names:
Pituitary adenylate cyclase-activating polypeptide type II receptor; VPAC1
Alternative UPACC:
P32241; A5JUT9; B3KPV1; B4DEB5; B4DGI4; F5H1F5; G3V0I1; Q15871; Q6P2M6
Background:
Vasoactive intestinal polypeptide receptor 1 (VIPR1), also known as VPAC1, is a critical receptor that binds vasoactive intestinal polypeptide (VIP) with high affinity. Its activity is mediated through G proteins that activate adenylyl cyclase, leading to increased levels of cyclic AMP. VIPR1 shows a preference for VIP over pituitary adenylate cyclase-activating polypeptide (PACAP-27 and PACAP-38), highlighting its specificity in cellular signaling pathways.
Therapeutic significance:
Understanding the role of Vasoactive intestinal polypeptide receptor 1 could open doors to potential therapeutic strategies. Its involvement in cyclic AMP signaling pathways suggests its potential impact on diseases where these pathways are dysregulated. Exploring VIPR1's functions and interactions could lead to novel treatments for such conditions.